Onyx kept at neutral by Merrill

Onyx Pharmaceuticals was maintained at a neutral rating by Merrill Lynch analyst Eric Ende on what the analyst termed a fourth-quarter earnings "non-event." The company reported a loss for the quarter of $1.00 per share, essentially in line with Merrill's estimate. Onyx continues to prohibit its distributors from releasing Nexavar sales data and did not provide guidance for 2006 Nexavar revenue. Since two new drugs for renal cell cancer launched almost simultaneously, early Nexavar sales could be lower than expected. Sutent survival data, possibly available in 2006, may provide an advantage for Sutent. Shares of the Emeryville, Calif., biopharmaceutical company were down 89 cents, or 3.12%, at $27.46 on volume of 929,494 shares versus the three-month running average of 1,005,990 shares. (Nasdaq: ONXX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.